Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus; Richard A. Larson; Francois Guilhot; Jerald P. Radich; Susan Branford; Timothy P. Hughes; Michele Baccarani; Michael W. Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D. Menssen; Hagop Kantarjian; Stephen G. O'Brien; Brian J. Druker; IRIS Investigators

doi:10.1056/NEJMoa1609324

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, Francois Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O'Brien, Brian J. Druker, IRIS Investigators

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	917-927
Journal	New England Journal of Medicine
Volume	376
Issue number	10
DOIs	https://doi.org/10.1056/NEJMoa1609324
Publication status	Published - 9 Mar 2017

Access to Document

10.1056/NEJMoa1609324

Cite this

Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C-E., Menssen, H. D., Kantarjian, H., O'Brien, S. G., Druker, B. J., & IRIS Investigators (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 376(10), 917-927. https://doi.org/10.1056/NEJMoa1609324

@article{41658cf2aeb74db38cd3e3be1eaba9ea,

title = "Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia",

author = "Andreas Hochhaus and Larson, {Richard A.} and Francois Guilhot and Radich, {Jerald P.} and Susan Branford and Hughes, {Timothy P.} and Michele Baccarani and Deininger, {Michael W.} and Francisco Cervantes and Satoko Fujihara and Christine-Elke Ortmann and Menssen, {Hans D.} and Hagop Kantarjian and O'Brien, {Stephen G.} and Druker, {Brian J.} and {IRIS Investigators} and GJ Ossenkoppele",

year = "2017",

month = mar,

day = "9",

doi = "10.1056/NEJMoa1609324",

language = "English",

volume = "376",

pages = "917--927",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "10",

}

Hochhaus, A, Larson, RA, Guilhot, F, Radich, JP, Branford, S, Hughes, TP, Baccarani, M, Deininger, MW, Cervantes, F, Fujihara, S, Ortmann, C-E, Menssen, HD, Kantarjian, H, O'Brien, SG, Druker, BJ & IRIS Investigators 2017, 'Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia', New England Journal of Medicine, vol. 376, no. 10, pp. 917-927. https://doi.org/10.1056/NEJMoa1609324

TY - JOUR

T1 - Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

AU - Hochhaus, Andreas

AU - Larson, Richard A.

AU - Guilhot, Francois

AU - Radich, Jerald P.

AU - Branford, Susan

AU - Hughes, Timothy P.

AU - Baccarani, Michele

AU - Deininger, Michael W.

AU - Cervantes, Francisco

AU - Fujihara, Satoko

AU - Ortmann, Christine-Elke

AU - Menssen, Hans D.

AU - Kantarjian, Hagop

AU - O'Brien, Stephen G.

AU - Druker, Brian J.

AU - IRIS Investigators

AU - Ossenkoppele, GJ

PY - 2017/3/9

Y1 - 2017/3/9

U2 - 10.1056/NEJMoa1609324

DO - 10.1056/NEJMoa1609324

M3 - Article

C2 - 28273028

SN - 0028-4793

VL - 376

SP - 917

EP - 927

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 10

ER -